9月24日，英派药业-B盘中下跌8.05%，报13.93港元，成交额3770.61万港元。
该股此前因核心产品塞纳帕利获欧洲药品管理局（EMA）人用药品委员会（CHMP）积极意见，建议批准其用于晚期卵巢癌等维持治疗的上市许可，股价在9月21日单日大涨逾27%，盘中一度涨超40%至20.56港元，短期累计涨幅显著。经历快速拉升后，获利回吐压力加大。与此同时，生物科技板块整体承压，康方生物跌3.54%、荣昌生物跌5.71%、三生制药跌3.7%、信达生物跌3.53%，板块联动下行对个股形成拖累。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.